Alleviant Medical Closes $75M in Financing
Alleviant Medical, Inc. secured $75M in equity financing led by S3 Ventures and RiverVest Venture Partners to fund the ALLAY-HF trial, testing the Alleviant System's safety and efficacy for heart failure treatment without implants. The trial aims to improve life quality for chronic heart failure patients globally.
Reference News
Alleviant Medical, Inc. secured $75M in equity financing led by S3 Ventures and RiverVest Venture Partners for its no-implant interatrial shunt to treat heart failure. The funds will support the global pivotal trial ALLAY-HF, aiming to demonstrate the Alleviant System's safety and efficacy. The system has shown clinical improvement in studies and received FDA Breakthrough Device Designation in 2021.
Alleviant Medical secured $75M funding for a global trial of its no-implant interatrial shunt system, ALLAY-HF, aiming to treat heart failure with a less invasive approach. The trial targets chronic heart failure patients, evaluating the system's safety and effectiveness, with significant clinical improvements already observed in preliminary studies.
Alleviant Medical, Inc. secured $75M in equity financing led by S3 Ventures and RiverVest Venture Partners to fund the ALLAY-HF trial, testing the Alleviant System's safety and efficacy for heart failure treatment without implants. The trial aims to improve quality of life for chronic heart failure patients.
Alleviant Medical secured $75M for a global trial of its interatrial shunt device to treat heart failure. The FDA-approved ALLAY-HF study aims to validate the Alleviant System's safety and efficacy, offering a less-invasive treatment by reducing left atrium pressure without implants.
Alleviant Medical, Inc. secured $75M in equity financing led by S3 Ventures and RiverVest Venture Partners to fund the ALLAY-HF trial, testing the Alleviant System's safety and efficacy for heart failure treatment without implants. The trial aims to improve life quality for chronic heart failure patients globally.